Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Does Preemptive Stem Cell Transplant Have Value for Patients at Genetic Risk for Leukemia?
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Flow Cytometry as a Relapse Risk Assessment Tool in T-Cell Acute Lymphoblastic Leukemia
An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Efficacy of Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia
The majority of patients achieved complete remission with or without incomplete count recovery after receiving 12 cycles of combination therapy.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Greater Infection Risk With Unrelated Transplant Donors in Pediatric Acute Lymphoblastic Leukemia
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Identifying Risk Factors for Second Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Low Response Rates to Hypomethylating Agents in Chronic Myelomonocytic Leukemia
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
Novel Postremission Therapeutic Agents for Patients With Acute Myeloid Leukemia
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Induction Chemotherapy Intensity May Not Influence Survival in Acute Myeloid Leukemia
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Long-Term Outcomes of Ibrutinib in Chronic Lymphocytic Leukemia
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
The Influence of Smoking Status on Survival and Relapse in Acute Myeloid Leukemia
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Rates of Transcript Variants in Chronic Myeloid Leukemia Associated With Sex and Age
The e13a2 transcript was expressed more frequently in men and pediatric patients.
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
The Cost of Cancer Treatment: Financial Toxicity in Acute Leukemia
What is the role of the clinician in managing financial toxicity?
A Changing Landscape: The Future of Treatment for Acute Myeloid Leukemia
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
“Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Increased Incidence of Second Malignancies in Patients With Chronic Myeloid Leukemia
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Conditioning Chemotherapy Preceding CAR T-Cell Therapy Appears to Be Safe in Relapsed/Refractory CLL
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Leukemia: What Your Patients Need to Know
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.
Effects of HLA Dimorphism on Clinical Outcomes of Immunotherapy in Acute Myeloid Leukemia
Patients carrying the -21M variant of HLA-B demonstrated more favorable clinical outcomes than patients carrying the -21T variant.
Managing Infectious Risk in Patients With Hematologic Malignancies
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
Measurable Residual Disease: A Step Toward Personalized Treatment for Acute Myeloid Leukemia
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
Antithrombin and Fibrinogen as Proxies for L-Asparaginase Activity in Pediatric Acute Lymphoblastic Leukemia
The combination of antithrombin activity and fibrinogen levels demonstrated optimal accuracy in detecting subtherapeutic L-asparaginase levels.
Relapse Risk in Pediatric Acute Myeloid Leukemia With Granulocyte Colony-Stimulating Factor
Relapse risk increased with cumulative granulocyte colony-stimulating factor dosage but appeared to level out at approximately 75 mg/kg to 100 mg/kg.
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Standardization of Minimal Residual Disease Measurements in Philadelphia-Positive ALL
Variability in minimal residual disease measurement techniques inhibits the ability to compare data across laboratories and clinical trials.
Challenges Remain, New Therapies Needed for Pediatric Lymphoblastic Lymphoma
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Improved Long-Term Outcomes After Stronger Postinduction Intensification for Acute Lymphoblastic Leukemia
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
Standardizing Parent Education for Patients With Acute Lymphoblastic Leukemia
With advances in cancer research and treatments, patients with acute lymphoblastic leukemia (ALL) can enjoy longer lives and treatment can continue long after initial hospital admission and into the outpatient setting.1,2 Parents of children with leukemia often find themselves serving as direct caregivers for their children, an important role that may require them to receive…
Cytogenetic Abnormalities Provide Prognostic Value in Predicting Acute Myeloid Leukemia Outcomes
Specific cytogenetic abnormalities are associated with patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and may have prognostic value, according to a study published in Leukemia. A multinational research team conducted a retrospective analysis of clinical outcomes of patients with AML undergoing allogeneic HSCT while taking into account recurring…
Antibiotic Discontinuation in Neutropenic Patients With Acute Myeloid Leukemia
Discontinuing antibacterial therapy in neutropenic patients with acute myeloid leukemia did not lead to excessive mortality or severe infections.
Current Standing and Future Directions of CAR T Therapy for Chronic Lymphocytic Leukemia
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Updated Acute Promyelocytic Leukemia Treatment Guidelines From the European LeukemiaNet
An expert panel from the European LeukemiaNet discussed optimal treatment strategies for patients with acute promyelocytic leukemia.
Guideline for Classifying Emetogenicity of Chemotherapy Agents in Pediatric Patients
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
The Role of Immune Checkpoint Inhibitors in Treating Hematologic Malignancies
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
Treating Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Options Remain Limited
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
Glucagon-Like Peptide-1 May Predict Inflammation in High-Dose Chemotherapy With Autologous Stem Cell Transplantation
Researchers measured levels of glucagon-like peptide-1 and C-reactive protein to determine their value as predictive biomarkers of toxicity.
Long-Term Outcomes of Anti-T-Lymphocyte Globulin Added to Graft-Versus-Host Disease Prophylaxis
GVHD prophylaxis including anti-T-lymphocyte globulin was associated with improved survival and quality of life.
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
